Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25837938 | 1.00 | VCAM1 (0.59) | VCAM1ALDH1A1HIF1ALMNATRPV4 | |
| Fluoride SCHEMBL28618487 | 0.98 | VCAM1 (0.57) | VCAM1ALDH1A1HIF1ALMNATRPV4 | |
| SCHEMBL594390 | 0.85 | VCAM1 (0.64) | VCAM1ALDH1A1HIF1ALMNATSHR | |
| SCHEMBL6153777 | 0.82 | ALOX12 (0.50) | VCAM1ALDH1A1LMNATRPV4SMN1; SMN2 | |
| SCHEMBL73860 | 0.82 | VCAM1 (0.70) | VCAM1ALDH1A1LMNATSHRGAA | |
| Fluoride SCHEMBL28259583 | 0.81 | VCAM1 (0.68) | VCAM1ALDH1A1LMNATSHRGAA | |
| SCHEMBL82629 | 0.79 | VCAM1 (0.66) | VCAM1ALDH1A1HIF1ALMNATSHR | |
| SCHEMBL27621933 | 0.79 | ALDH1A1 (0.58) | VCAM1ALDH1A1HIF1ALMNATSHR | |
| SCHEMBL2649443 | 0.78 | VCAM1 (0.48) | VCAM1ALDH1A1HIF1ALMNAGAA | |
| SCHEMBL3173442 | 0.78 | XDH (0.60) | VCAM1ALDH1A1LMNATSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109369412-A | A kind of preparation method of the fluoro- 4- nitrobenzoic acid of 2,5- bis- | 常州大学 | 2019-02-22 | — | — | CN | claimed |
| CN-103694137-A | Production method of 2-fluorine-4-nitrobenzonitrile | CHANGZHOU INST ENG TECH | 2014-04-02 | — | — | CN | claimed |
| CN-101648890-B | Synthesis method of 2-fluoro-4-nitrobenzonitrile | CHANGZHOU INST ENG TECH | 2012-07-25 | — | — | CN | claimed |
| CN-101648890-A | Synthesis method of 2-fluoro-4-nitrobenzonitrile | CHANGZHOU INST OF ENGINEERING | 2010-02-17 | — | — | CN | claimed |
| EP-4748837-A1 | AROMATIC AMIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM16A LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4638454-A1 | SUBSTITUTED IMIDAZO-BASED COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | Celgene Corporation (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4547662-A1 | IMIDAZO[4,5-B]PYRIDINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS SIK MODULATORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | F. Hoffmann-La Roche AG (CH) | 2025-05-07 | — | — | EP | disclosed |
| US-20250127780-A1 | IMIDAZO[4,5-B]PYRIDINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS SIK MODULATORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | HOFFMANN-LA ROCHE INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4514790-A1 | COMPOUNDS FOR INHIBITING KIF18A | Volastra Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119451951-A | Compounds for inhibition of KIF18A | 沃拉斯查疗法公司 | 2025-02-14 | — | — | CN | disclosed |
| WO-2000039108-A1 | THROMBIN OR FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
| CN-1218456-A | Irreversible inhibitors of tyrosine kinases | WARNER LAMBERT CO (US) | 1999-06-02 | — | — | CN | disclosed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| EP-0544488-B1 | Substituted phenyl phenol leukotriene antagonists | LILLY CO ELI (US) | 1998-03-11 | — | — | EP | disclosed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
| CN-1035001-C | Substituted phenyl phenol leukotriene antagonists | LILLY CO ELI (US) | 1997-05-28 | — | — | CN | disclosed |
| CN-1088906-A | The phenyl phenol leukotriene antagonists that replaces | LILLY CO ELI (US) | 1994-07-06 | — | — | CN | disclosed |
| EP-0544488-A2 | Substituted phenyl phenol leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552770-B2 | Compounds for treating respiratory disease | TMEM109, SCN1A, SLC16A1 | VCAM1 988/4885ALDH1A1 596/4885HIF1A 496/4885 |
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | VCAM1 4028/4885ALDH1A1 911/4885HIF1A 1073/4885 |
| US-20250127780-A1 | IMIDAZO[4,5-B]PYRIDINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS SIK MODULATORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | SIK1, SIK2, SIK3 | VCAM1 3179/4885ALDH1A1 830/4885HIF1A 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.